Press Releases

Month Year

Month Year

Apr 24, 2018

Evofem Biosciences Announces Proposed Public Offering of Common Stock
Feb 21, 2018

Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia
Feb 16, 2018

Evofem Biosciences to Present at RBC Global Healthcare Conference
Feb 15, 2018

Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

Trial Data Expected First Quarter 2019
Jan 23, 2018

Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

STI Trial Investigates Amphora for Prevention of Urogenital Chlamydia Trachomatis Infection in Women
Jan 17, 2018

Evofem Announces Closing Of Merger With Neothetics

Commences Trading on NASDAQ Capital Market on Thursday, January 18, 2018 Under Ticker Symbol "EVFM"
Nov 16, 2017

Form S-4 Filed with SEC
Oct 17, 2017

Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company
Jul 27, 2017

Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) for Prevention of Pregnancy
Jun 29, 2017

AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

Show per page